NICE: Brentuximab Vedotin for Untreated sALCL

Dawn O'Shea

July 10, 2020

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending brentuximab vedotin (Adcetris, Takeda) with cyclophosphamide, doxorubicin, and prednisone (CHP) for untreated systemic anaplastic large cell lymphoma (sALCL) in adults. The decision suggests brentuximab vedotin with CHP will replace cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for sALCL in the NHS.

The randomised controlled ECHELON-2 trial (n=452) found that, compared with CHOP, brentuximab vedotin with CHP was associated with greater progression free survival (PFS) and overall survival (OS) in patients with sALCL.

There is uncertainty about the modelling, but the most likely cost-effectiveness estimate is within what NICE considers an acceptable use of NHS resources.

The list price of brentuximab vedotin is £2500 per 50 mg vial. Based on a mean of six cycles, the cost for an average patient is estimated at about £47,619, at list price. The treatment is being made available on the NHS at a discounted price.

The draft guidance has been sent to consultees for appraisal. The consultees have 15 working days to consider appealing the decision. Subject to an appeal, the final decision is expected by 12 August.

This article originally appeared on Univadis, part of the Medscape Professional Network.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: